<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35166899</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1433-7339</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>30</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</Title>
          <ISOAbbreviation>Support Care Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A retrospective comparison of haloperidol and hydroxyzine combination therapy with haloperidol alone in the treatment of overactive delirium.</ArticleTitle>
        <Pagination>
          <StartPage>4889</StartPage>
          <EndPage>4896</EndPage>
          <MedlinePgn>4889-4896</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00520-022-06903-z</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">For the treatment of delirium, antipsychotics such as haloperidol are used as standard treatments. However, haloperidol has a little sedative effect and may not be sufficiently effective in controlling overactive delirium. Hydroxyzine, an antihistamine, may be used in combination with haloperidol to supplement its sedative effect. The aim of this study was to investigate the effect of haloperidol alone or in combination with hydroxyzine on the improvement of overactive delirium retrospectively.</AbstractText>
          <AbstractText Label="METHOD" NlmCategory="METHODS">Delirium was assessed from medical records using the Intensive Care Delirium Screening Checklist (ICDSC). The number of patients and days with an ICDSC score of &lt; 4, indicating an absence of delirium after haloperidol alone or haloperidol and hydroxyzine was surveyed for 6 days.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 157 patients were diagnosed with delirium from April 2019 to July 2021, of which 18 patients received haloperidol alone, and 21 patients received the combination of haloperidol and hydroxyzine for overactive delirium. The number of patients with a mean ICDSC score of &lt; 4 on days 1-6 was two patients (11%) in the haloperidol groups and two patients (10%) in the combination of haloperidol and hydroxyzine group (P = 0.999). The days within &lt; 4 of the ICDSC score on days 1-6 were 0.8 (1.3) and 0.8 (1.5), respectively (P = 0.848).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Haloperidol alone and haloperidol plus hydroxyzine are both effective in the treatment of overactive delirium. However, the concomitant use of hydroxyzine with haloperidol may not improve the efficacy of treatment of overactive delirium compared to haloperidol alone.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sato</LastName>
            <ForeName>Junya</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-2478-0190</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara City, Tochigi Prefecture, 329-2763, Japan. junya02377@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, International University of Health and Welfare, Ohtawara City, Kitakanemaru, Tochigi Prefecture, 2600-1324-8501, Japan. junya02377@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanaka</LastName>
            <ForeName>Rei</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Shizuoka Prefecture, 411-8777, Sunto-gun, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 YamazakiChiba Prefecture, 278-8510, Noda City, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Support Care Cancer</MedlineTA>
        <NlmUniqueID>9302957</NlmUniqueID>
        <ISSNLinking>0941-4355</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>30S50YM8OG</RegistryNumber>
          <NameOfSubstance UI="D006919">Hydroxyzine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J6292F8L3D</RegistryNumber>
          <NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003693" MajorTopicYN="Y">Delirium</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006919" MajorTopicYN="N">Hydroxyzine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006993" MajorTopicYN="N">Hypnotics and Sedatives</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Delirium</Keyword>
        <Keyword MajorTopicYN="N">Haloperidol</Keyword>
        <Keyword MajorTopicYN="N">Hydroxyzine</Keyword>
        <Keyword MajorTopicYN="N">Intensive Care Delirium Screening Checklist (ICDSC)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>12</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35166899</ArticleId>
        <ArticleId IdType="doi">10.1007/s00520-022-06903-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s00520-022-06903-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>American Psychiatric Association, DSM-5 Task Force (2013) Diagnostic and statistical manual of mental disorders: DSM-5™ (5th ed.). American Psychiatric Publishing, Inc. Washington, DC</Citation>
        </Reference>
        <Reference>
          <Citation>Folstein MF, Bassett SS, Romanoski AJ, Nestadt G (1991) The epidemiology of delirium in the community: the Eastern Baltimore Mental Health Survey. Int Psychogeriatr 3:169–176</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1041610291000637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dyer CB, Ashton CM, Teasdale TA (1995) Postoperative delirium. A review of 80 primary data-collection studies. Arch Intern Med 155:461–5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archinte.1995.00430050035004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawlor PG, Gagnon B, Mancini IL, Pereira JL, Hanson J, Suarez-Almazor ME, Bruera ED (2000) Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 160:786–794</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archinte.160.6.786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S (2012) Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 344:e977.  https://doi.org/10.1136/bmj.e977</Citation>
        </Reference>
        <Reference>
          <Citation>Tahir TA, Eeles E, Karapareddy V, Muthuvelu P, Chapple S, Phillips B, Adyemo T, Farewell D, Bisson JI (2010) A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. J Psychosom Res 69:485–490</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpsychores.2010.05.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breitbart W, Tremblay A, Gibson C (2002) An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 43:175–182</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/appi.psy.43.3.175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kishi Y, Kato M, Okuyama T, Thurber S (2012) Treatment of delirium with risperidone in cancer patients. Psychiatry Clin Neurosci 66:411–417</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1819.2012.02346.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burry L, Hutton B, Williamson DR, Mehta S, Adhikari NK, Cheng W, Ely EW, Egerod I, Fergusson DA, Rose L (2019) Pharmacological interventions for the treatment of delirium in critically ill adults. Cochrane Database Syst Rev 9(9):CD011749.  https://doi.org/10.1002/14651858.CD011749.pub2</Citation>
        </Reference>
        <Reference>
          <Citation>Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y (2001) Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med 27:859–864</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s001340100909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hui D, Frisbee-Hume S, Wilson A, Dibaj SS, Nguyen T, De La Cruz M, Walker P, Zhukovsky DS, Delgado-Guay M, Vidal M, Epner D, Reddy A, Tanco K, Williams J, Hall S, Liu D, Hess K, Amin S, Breitbart W, Bruera E (2017) Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: A randomized clinical trial. JAMA 318:1047–1056</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2017.11468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuo N, Morita T (2007) Efficacy, safety, and cost effectiveness of intravenous midazolam and flunitrazepam for primary insomnia in terminally ill patients with cancer: a retrospective multicenter audit study. J Palliat Med 10:1054–1062</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/jpm.2007.0016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baillargeon J, Singh G, Kuo YF, Raji MA, Westra J, Sharma G (2019) Association of opioid and benzodiazepine use with adverse respiratory events in older adults with chronic obstructive pulmonary disease. Ann Am Thorac Soc 16:1245–1251</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1513/AnnalsATS.201901-024OC</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hui D, De La Rosa A, Wilson A, Nguyen T, Wu J, Delgado-Guay M, Azhar A, Arthur J, Epner D, Haider A, De La Cruz M, Heung Y, Tanco K, Dalal S, Reddy A, Williams J, Amin S, Armstrong TS, Breitbart W, Bruera E (2020) Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial. Lancet Oncol 21:989–998</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(20)30307-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuma R, DeAngelis LM (2000) Altered mental status in patients with cancer. Arch Neurol 57:1727–1731</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.57.12.1727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcantonio ER, Juarez G, Goldman L, Mangione CM, Ludwig LE, Lind L, Katz N, Cook EF, Orav EJ, Lee TH (1994) The relationship of postoperative delirium with psychoactive medications. JAMA 272:1518–1522</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.1994.03520190064036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini JV, Leo-Summers LS, Inouye SK (2001) Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med 161:2091–2097</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archinte.161.17.2091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beach SR, Gross AF, Hartney KE, Taylor JB, Rundell JR (2020) Intravenous haloperidol: a systematic review of side effects and recommendations for clinical use. Gen Hosp Psychiatry 67:42–50</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.genhosppsych.2020.08.008</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
